Stock

ELVN

ENLIVEN THERAPEUTICS, INC.

Latest close $403 of 27 marquee funds currently hold1 CUSIP mapped

Current holders

27 funds tracked

Ever held

Current + past

New this quarter

Exited this quarter

Marquee-fund ownership over time

Aug 14, 2024May 14, 2025Feb 12, 2026May 15, 2026

Now

This quarter's activity

New positions opened

D.E. Shaw
Q2 2026 · 193,531 shares
+$7.67M

Positions exited

Point72 Asset Management
Q2 2026 · +132%
EXIT

Current holders

Sorted by tenure (longest first)

Fund	First disclosed	Held	Entry price	Latest close	Return on entry
Citadel Advisors	Q3 2024(8Q snapshot)	7Q	$22	$40	+82%
Millennium Management	Q4 2024(8Q snapshot)	6Q	$25	$40	+59%
D.E. Shaw	Q2 2026(8Q snapshot)	1Q	$41	$40	-4%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point

Fund	Last entry	Exited	Entry → Exit	Return
Point72 Asset Management	Q2 2025	Q2 2026	→ $41	+132%
Duquesne Family Office	Q3 2025	Q1 2026	→ $26	+29%
Renaissance Technologies	Q2 2025	Q1 2026	→ $27	+37%
Two Sigma Investments	Q3 2024	Q2 2025	→ $18	-18%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Enliven Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d

Filings · last 90d

Total on file

320

Recent SEC buffer

Most recent

Jun 9, 2026

30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 320 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · ENLIVEN THERAPEUTICS, INC.

Annual figures sourced directly from ENLIVEN THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income

-$103.69M

FY2025-16% YoY

EPS (diluted)

$-1.83

FY2025+3% YoY

Free cash flow(?)

-$70.3M

FY2025+4% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Enliven Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds

Fund	Open date	Close date	Open price	Close price / current	Return
D.E. Shaw	Q2 2026	open	$41	$40	-4%
Duquesne Family Office	Q3 2025	Q1 2026	$20	$26	+29%
Point72 Asset Management	Q2 2025	Q2 2026	$18	$41	+132%
Renaissance Technologies	Q2 2025	Q1 2026	$20	$27	+37%
Millennium Management	Q4 2024	open	$25	$40	+59%
Citadel Advisors	Q3 2024	open	$22	$40	+82%
Two Sigma Investments	Q3 2024	Q2 2025	$22	$18	-18%

Caveats

Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
“Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.